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Abstract
Background: Resistance of Plasmodium falciparum to atovaquone in vitro and in vivo has been
associated to mutations in the parasite cytochrome b gene.
Methods: Cultures were sequentially subjected to increasing doses of atovaquone alone or in
combination with cycloguanil and the cytochrome b gene was sequenced. Additionally, we
investigated the parasite cytochrome b gene of a patient returning from Mali with Malarone®
treatment failure in vivo.
Results: All strains that survived atovaquone concentrations in vitro of 2 × 10-8 to 2 × 107 M
showed the M133I mutation and one strain with the highest atovaquone concentration the
additional mutation L171F. Sequencing of the in vivo treatment failure revealed a point mutation at
codon 268 resulting in an amino acid change from tyrosine to serine. Based on the repeated
emergence of mutations at codon 268, but no detection of alterations at codon 133 in vivo, we
developed a detection method for the diagnostic of codon 268 polymorphisms as a potential
atovaquone/proguanil resistance marker. A nested PCR with 3 different pairs of primers for the
second round was designed. Each product was digested with restriction enzymes, capable to
distinguish the wild type from the two reported mutations at codon 268.
Conclusion: Mutations at codon 268 of the parasite cytochrome bc1 gene are associated with
atovaquone/proguanil treatment failure in vivo and can be used as potential resistance marker This
method provides a novel and robust tool to investigate the relevance of codon 268 polymorphisms
as resistance marker and to monitor the further emergence of atovaquone/proguanil resistance.
Background
The rapid emergence of resistance to standard antimalar-
ial drugs has become a serious global health problem in
endemic countries. For affected travellers returning to in-
dustrialised countries, effective treatment is available and
resistance is as yet not a frequent problem in the treatment
of falciparum malaria. The recently introduced drug Ma-
larone® is a combination of atovaquone and proguanil
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evidence that parasites may quickly develop resistance to
atovaquone and proguanil. When treated with
atovaquone alone, one study showed that 33% of patients
experienced recrudescence of parasitaemia [1]. In combi-
nation with proguanil, cure rates from 99–100% were
achieved [2–7]. In 2002, the first case of in vivo resistance
to atovaquone and proguanil in a non-immune European
traveller, returning from Nigeria, was reported [8].
Atovaquone acts by inhibiting mitochondrial electron
transport [9] and collapsing mitochondrial membrane
potential [10]. It has been suggested that atovaquone,
based on its structural similarity to ubiquinol, binds to the
parasitic cytochrome bc1 [11]. Mutations in the cyto-
chrome bc1 gene of the parasite mitochondrial genome
have been described as confering atovaquone resistance.
Two mutations in Pneumocystis carinii at the ubiquinol-
binding pocket (Q0 domain) are associated with
atovaquone prophylaxis failure [12]. In in vitro resistant
Toxoplasma gondii lines two mutations at codon 129 and
254 were found to confer atovaquone resistance.
Atovaquone-resistant Plasmodium yoelii lines have been
derived by sub-therapeutic treatment of infected mice.
Five mutations near the putative atovaquone binding
pocket have been identified, including a substitution of
tyrosine by cysteine at codon 268 [13]. In a similar study
three mutations at the cytochrome b gene of atovaquone
resistant Plasmodium berghei lines were found to be associ-
ated with resistance to atovaquone. The mutations at co-
don 133 or 144, in addition to an amino acid change at
codon 284, led to increased resistance levels.[14].
Atovaquone resistant lines of Plasmodium falciparum have
been derived in vitro by surviving various concentrations
[15]. An initial mutation at codon 133 was found to con-
fer low resistance, which could be increased by an addi-
tional mutation in the domain from codon 272 to codon
280.
In vivo the cytochrome bc1 sequence of a P. falciparum iso-
late from a Thai patient with recrudescence after
atovaquone and pyrimethamine treatment showed a mu-
tation at codon 268 resulting in the substitution of tyro-
sine by serine [1,15]. An amino acid change to asparagine
at the same codon was described in an English patient
travelling to Nigeria who failed atovaquone/proguanil
therapy [8].
In this report we describe laboratory derived mutations of
the cytochrome bc1 gene of P. falciparum after sub-curative
administration of atovaquone alone or in combination
with cycloguanil. These in vitro changes have been com-
pared with mutations of an in vivo isolate derived from a
patient with recrudescence after atovaquone/proguanil
treatment. Based on this information we developed a nov-
el PCR-RFLP method for the detection of mutations at co-
don 268, associated with resistance to atovaquone/
proguanil.
Material and Methods
In vitro induction of atovaquone resistance
The P. falciparum laboratory line K1 [16] was cultivated in
vitro according to Trager & Jensen [17] with 5% haemat-
ocrit and medium containing RPMI, glucose, gentamycine
sulfat, hepes, sodium bicarbonate, hypoxanthine (all pur-
chased from SIGMA-ALDRICH, Taufkirchen, Germany)
and human sera. Fresh erythrocytes and plasma bottles
were purchased from the Red Cross. Cultures were split
every 2 days according to cell growth. The selection of
drug resistance followed a modified protocol of Korsincz-
ky, 2000 [15]. Parasites were first cultured in one flask and
split into eight cultures when parasitaemia reached ap-
proximately 2%. The eight cultures were maintained until
the parasitaemia reached approximately 5%. Parasitised
red blood cells from one of the eight flasks were cryopre-
served as the atovaquone-sensitive parent. From the re-
maining flasks, one was cultivated as control without
drugs, 3 were cultivated with medium containing 10-8 M
atovaquone and 3 flasks with 10-8 M atovaquone plus
0.88 ng/ml cycloguanil. Cycloguanil concentration was
calculated as atovaquone/proguanil ratio of 2.5 in Malar-
one® tablets and 30% metabolism of proguanil to cyc-
loguanil, achieving an atovaquone/cycloguanil ratio
(weight) of 8.33. The parasites that survived were sequen-
tially subjected to 2 × 10-8, 5 × 10-8, 10-7 and 2 × 10-7 M
atovaquone or the combination of atovaquone and cyc-
loguanil, respective. Aliquots of parasites were removed
after surviving each drug concentration for cryopreserva-
tion and DNA preparation.
In vivo resistance
The blood sample TN352 of a P. falciparum case presented
after self treatment with a complete course of Malarone®
was collected within the network TropNetEurop. The sam-
ple NGATV01 of a Malarone® treatment failure was kindly
provided by Dr. Warhurst, London School of Hygiene and
Tropical Medicine/UK [8].
Sequencing of Plasmodium falciparum cytochrome b 
gene
Parasite DNA was extracted by use of BIO RAD InstaGene
Matrix. A fragment of the cytochrome bc1 gene was ampli-
fied as described by Korsinczky [15], using primers CYTb1
and CYTb2. PCR was carried out using 2.5 U Qiagen Hot-
star taq, 1.5 mM Mg2+, 1 µM of each primer and 0.2 mM
dNTP's. The reaction mixture was initially heated at 93°C
for 15 min and then cycled at 93°C for 50s, 45°C for 50s
and 72°C for 1 min over 40 cycles. PCR products were pu-
rified from the gel using Qiaex(II) Kit (Qiagen) and ligat-
ed into the pCR®2.1 Topo vector (Invitrogen TA-TOPOPage 2 of 7
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transformed with the ligation mix and positive clones se-
lected and propagated. The plasmids were prepared using
QIAprep Spin Plasmid Kit, then sequenced in both direc-
tions using ABI Prism Big dye Terminator kit employing
the vector primers M13 forward and M13 reverse and the
internal primers CYTb3 and CYTb4, with a 3 times cover-
age of the gene. [15]. Sequencing was done on ABI Prism
377 (Perkin-Elmer), proof-reading and translation was
done using Seqman software from DNAstar, or was out-
sourced to MWG Biotech (MWG-Biotech Ebersberg,
Germany).
PCR-RLFP method for codon 268 mutations
A nested PCR was designed using CYTb1 and CYTb2 as
outer primers and 3 different pairs of nested primers to
distinguish the 3 known polymorphisms at codon 268.
Primer sequences are shown in table 1. PCR product sizes
are listed in table 2. For the primary amplification reac-
tion a mix containing 0.125 µM of each outer primer, 0.2
mM dNTP's, 1.5 mM Mg2+ and 0.5 U Taq polymerase
(Qbiogene, Carsbad, Canada) was initially heated at
94°C for 5 min and then cycled at 94°C for 50s, 50°C for
50s and 70°C for 1 min over 35 cycles with a final exten-
sion at 70°C for 5 min. For the secondary amplification,
1 µl of PCR product was added to the mastermix contain-
ing 0.5 µM primers and dNTP, MgCl2, Taq Polymerase as
above. PCR conditions were 94°C for 5 min, 30 cycles of
95°C for 30s, 55°C for 30s and 72°C for 30s and a final
extension at 72°C for 5 min for the primer pairs CYTb3/
CYTb5 as well as for CYTb2/CYTb6. CYTb2/CYTb7 were
annealed at 45°C. The products of the second round were
confirmed by electrophoresis in ethidium bromide-
stained agarose gel.
For RFLP analysis 5 µl of PCR product was mixed with 1
U of the appropriate enzyme (see Table 2) and its specific
buffer in a total volume of 22 µl and incubated at 37°C
over night. The result was detected by electrophoresis in
ethidium bromide-stained agarose gel.
Results
In vitro induction of resistance against atovaquone alone 
or the combination of atovaquone and cycloguanil in a P. 
falciparum K1 strain results in mutations in the cyto-
chrome bc1 gene
All parasites that survived an atovaquone concentration of
2 × 10-8 M, 1 × 10-7 M and 2 × 10-7 in the medium showed
a single base mutation at position 399 in the cytochrome
bc1 gene. The mutation resulted in an amino acid change
from methionine (ATG) to isoleucine (ATT) at codon 133
(M133I). The same mutation was seen in parasites that
were cultured in a medium containing the same concen-
tration of atovaquone in combination with cycloguanil.
The parasite line AT200 survived 2 × 10-7 M atovaquone
in the medium. Sequencing of the cytochrome bc1 gene
identified a additional mutation at position 813 resulting
in an amino acid change at codon 271 from leucine (TTA)
to phenylalanine (TTC).








* Small letters indicate base changes to provide digest sites for restriction enzymes to distinguish wild type from mutations at codon 268
Table 2: Method for detecting codon 268 mutations: primer pairs for amplification with size of amplification product and restriction 
enzyme for following digest
Codon 268 Type Primer pair Product size Cutting enzyme Fragment length
Outer PCR CYTb1 + CYTb2 939 bp
TAT Wild type CYTb3 + CYTb5 384 bp NsiI 359 + 25
TCT Y268S CYTb2 + CYTb6 171 bp AlwNI 147 + 24
AAT Y268N CYTb2 + CYTb7 174 bp SspI 150 + 24
NsiI cuts TAT; AlwNI cuts TCT; SspI cuts TAT and TCT, but not AATPage 3 of 7
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268 in the cytochrome bc1 gene
The blood sample was obtained at the outpatient depart-
ment of the Tropical Institute in Munich from a 28 year
old male traveller returning from Mali to Germany. After
developing signs of malaria and a positive result of the
Malaquick® rapid diagnostic test he took a complete
course of Malarone® complying with dose and concomi-
tant food administration and recovered. Four weeks later
he relapsed and presented with fever and 1.5% parasitae-
mia of P. falciparum asexual forms. The patient was suc-
cessfully treated with Riamet® (lumefantrine and
artemether).
The DNA was extracted and the parasite cytochrome bc1
coding region was cloned and sequenced together with
the DNA samples of the in vitro cultures. The sequence
showed a unique single base change from TAT to TCT at
the codon 268 resulting in an amino acid change from ty-
rosine to serine (Y268S).
Development of a PCR-RFLP method to detect mutations 
at codon 268 of the parasite cytochrome bc1 coding region 
that are associated with resistance to atovaquone/pro-
guanil in vivo
A nested PCR was designed with an outer product of 939
bp amplified with primer CYTb1 and CYTb2. In order to
have restriction sites that are able to distinguish the wild
type from the two reported mutations at codon 268, three
new primers have been designed (see Table 1). The second
amplification rounds used following pairs of primers:
CYTb3/CYTb5, CYTb2/CYTb6 and CYTb2/CYTb6. The
products was digested with NsiI, AlwNI and SspI, respec-
tively (see Table 2 for details). Primer sequences are given
in table 1 and fragment sizes after enzyme digest in table
2. NsiI cuts the wild type TAT, AlwNI cuts the mutation
type TCT, and SspI cuts all except the mutation type AAT.
The resulting pattern after restriction enzyme digest and
gel electrophoresis is shown at Figure 1. Fragment sizes
differ in 24 to 25 base pairs and require therefore a high
resolution gel and optimised running conditions of the
electrophoresis.
Discussion
Atovaquone is an antimalarial substance that leads to an
effective clearance of initial parasitaemia, but shows high
recrudescence rates when used in monotherapy [1]. In or-
der to improve the therapeutic response and slow the de-
velopment of drug resistance atovaquone is used in a fixed
combination with proguanil (Malarone®). Atovaquone
acts by collapsing the mitochondrial membrane potential
and therefore inhibiting parasite respiration [10]. Single
point mutations at the cytochrome bc1 gene of P. falci-
parum have been associated with atovaquone resistance
[15]. We investigated sequence changes on the P. falci-
parum cytochrome bc1 gene after exposure to atovaquone
alone and in combination with cycloguanil, the active me-
tabolite of proguanil. Cultures that survived atovaquone
concentrations from 2 × 10-8 up to 10-7 M alone or in
combination with cycloguanil showed a single point mu-
tation at codon 133 (ATG to ATT) resulting in an amino
acid change from methionine to isoleucine (M133I).
When subjected to 2 × 10-7 M atovaquone in the culture
medium, the parasites showed an additional mutation at
codon 271 (TTA to TTC) resulting in an amino acid
change from leucine to phenylalanine (L271F). No sec-
ond mutation was found for parasites that survived 2 × 10-
7 M atovaquone in combination with cycloguanil. The
M133I mutation has also been reported from an
atovaquone resistance line of P. berghei [14] but caused by
a change from ATG to ATA. A mutation at codon 271 (TTA
to GTA) has been described already for atovaquone resist-
ant P. yoelii lines (L271V) in combination with the K272R
mutation [13]. We found the mutation L271F in addition
to the M133I change. Tandem mutations composed of
M133I (ATG to ATA) with a second change in the region
of codon 272 to 280 at the cytochrome b gene have been
reported by Korsinczky et al. [15] after similar in vitro se-
lection of mutations. Similar to our findings, he described
an initial mutation at codon 133 resulting in a steric alter-
ation at the putative atovaquone binding site. While the
different tandem mutations do not affect predicted bind-
ing sites, they may enhance the alteration by the 133
substitution.
As we could demonstrate, the treatment of the K1 parasite
culture with both drugs at sub-curative dosages did not
prevent the development of the M133I mutation. Since
the laboratory strain K1 is resistant to cycloguanil, a pro-
tective effect of the combination can be expected at higher
doses of cycloguanil and has been shown for 2 × 10-7 M
atovaquone in combination with cycloguanil. The influ-
ence of proguanil on the development of resistance to Ma-
larone® in vitro has not been investigated. As in vitro study
showed, acts proguanil compared to cycloguanil by dis-
tinct activities and has a synergistic effect in combination
with atovaquone [18,19].
Sequencing of a P. falciparum clone derived from an in vivo
treatment failure with Malarone® detected a single point
mutation at codon 268 of the cytochrome b gene. The
change of TAT to TCT resulted in an amino acid substitu-
tion from tyrosine to serine (Y268S). The same mutation
has been described before in a Thai patient with recrudes-
cence after atovaquone and pyrimethamine treatment and
a 10,000 fold increase of IC50 to atovaquone [1,15]. Fivel-
man et al. [8] showed a case of Malarone® resistance in vivo
with 800 fold increase in IC50 to atovaquone and a change
to AAT at codon 268 resulting in a substitution to aspar-
agine (Y268N). Furthermore the Y268S mutation has alsoPage 4 of 7
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ed traveller returning from Cameroon to Denmark who
failed Malarone® therapy (personal communication, Kim
David). In all cases, the substitution of the bulky Tyr268
by less bulky amino acids in the region of the ubiquinol
oxidation site might affect the fit and binding of the drug.
The mutation at codon 133, although observed in vitro,
apparently does not influence development of in vivo re-
sistance to atovaquone/proguanil. However, the three
cases of confirmed atovaquone/proguanil resistance came
from West Africa where Malarone® is not widely used yet.
Increasing drug pressure with atovaquone/proguanil in
endemic areas may also select for the M133I mutation. In-
vestigations on atovaquone resistant K1 clones in vitro
found for the double amino acid mutation (M133I and
G280D) 5 to 9% loss of fitness compared to the sensitive
clone, but no detectable loss of fitness for the single mu-
tation M133I [18].
For the development of a diagnosis test for resistance to
atovaquone/proguanil we focused on the two mutations
at codon 268 of the parasite cytochrome bc1. Out of four
molecular analysed treatment failures to date with either
atovaquone/proguanil or atovaquone/pyrimethamine, all
four samples showed mutations at codon 268. Both ami-
Figure 1
Restriction digest method for detecting codon 268 mutations of cytochrome bc1 A: 384 bp amplification product 
with the primer pair CYTb3/CYTb5, digested by NsiI, K1 wild type (TAT) and AAT mutation (NGATV01) are cut (359 bp); B: 
171 bp amplification product with the primer pair CYTb2/CYTb6, digested by AlwNI, only TN352 with the TCT mutation is 
cut to a 147 bp product; C: 174 bp amplification product with the primer pair CYTb2/CYTb7, digested by SspI, TAT wild type 
(K1) and TCT mutation (TN352) are digested (150 bp), while AAT mutation (NGATV01) remains uncut.Page 5 of 7
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high increase of the IC50. Despite the low number of cases
described to date indicate these results the relevance of co-
don 268 polymorphisms as potential resistance marker.
To achieve a higher sensitivity, a nested PCR was designed
with 3 different seconds rounds. Primers that anneal near
the target mutations have been changed in one or two nu-
cleotides in order to create restriction sites. The TAT wild
type and the TCT mutation is demonstrated by the direct
cut of the PCR product, while the AAT mutation is indicat-
ed when SspI does not cut. This might be a disadvantage
of the method. However, with consequent use of positive
and negative controls this is a precise method for the de-
tection of codon 268 mutations.
Conclusions
Mutations at codon 268 of the parasite cytochrome bc1
gene are associated with atovaquone/proguanil treatment
failure in vivo and can be used as possible resistance mark-
er. Further work on more field isolates is required to prove
the fundamental role of codon 268 mutations to govern
drug resistance in the parasite. This new protocol permits
the screening of patient samples from different malaria
endemic regions and will be a useful tool in the context of
TropNetEurop http://www.tropnet.net, a clinical network
on imported infectious disease surveillance. Samples of
returning travellers are collected within the network and
examined continuously for molecular resistance markers
[21]. Imported isolates will be analysed for codon 268
mutations to gain data on the prevalence of those muta-
tions and their relevance for monitoring the further emer-
gence of Malarone® resistance.
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